1 Multiple Sclerosis Drugs Market Overview 1.1 Product Overview and Scope of Multiple Sclerosis Drugs 1.2 Multiple Sclerosis Drugs Segment by Type 1.2.1 Global Multiple Sclerosis Drugs Sales Growth Rate Comparison by Type (2020-2026) 1.2.2 Injectable Medications 1.2.3 Oral Medications 1.2.4 Others 1.3 Multiple Sclerosis Drugs Segment by Application 1.3.1 Multiple Sclerosis Drugs Sales Comparison by Application: (2020-2026) 1.3.2 Adults 1.3.3 Children 1.4 Global Multiple Sclerosis Drugs Market Size Estimates and Forecasts 1.4.1 Global Multiple Sclerosis Drugs Revenue 2015-2026 1.4.2 Global Multiple Sclerosis Drugs Sales 2015-2026 1.4.3 Multiple Sclerosis Drugs Market Size by Region: 2020 Versus 2026 2 Global Multiple Sclerosis Drugs Market Competition by Manufacturers 2.1 Global Multiple Sclerosis Drugs Sales Market Share by Manufacturers (2015-2020) 2.2 Global Multiple Sclerosis Drugs Revenue Share by Manufacturers (2015-2020) 2.3 Global Multiple Sclerosis Drugs Average Price by Manufacturers (2015-2020) 2.4 Manufacturers Multiple Sclerosis Drugs Manufacturing Sites, Area Served, Product Type 2.5 Multiple Sclerosis Drugs Market Competitive Situation and Trends 2.5.1 Multiple Sclerosis Drugs Market Concentration Rate 2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue 2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 2.7 Primary Interviews with Key Multiple Sclerosis Drugs Players (Opinion Leaders) 3 Multiple Sclerosis Drugs Retrospective Market Scenario by Region 3.1 Global Multiple Sclerosis Drugs Retrospective Market Scenario in Sales by Region: 2015-2020 3.2 Global Multiple Sclerosis Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020 3.3 North America Multiple Sclerosis Drugs Market Facts & Figures by Country 3.3.1 North America Multiple Sclerosis Drugs Sales by Country 3.3.2 North America Multiple Sclerosis Drugs Sales by Country 3.3.3 U.S. 3.3.4 Canada 3.4 Europe Multiple Sclerosis Drugs Market Facts & Figures by Country 3.4.1 Europe Multiple Sclerosis Drugs Sales by Country 3.4.2 Europe Multiple Sclerosis Drugs Sales by Country 3.4.3 Germany 3.4.4 France 3.4.5 U.K. 3.4.6 Italy 3.4.7 Russia 3.5 Asia Pacific Multiple Sclerosis Drugs Market Facts & Figures by Region 3.5.1 Asia Pacific Multiple Sclerosis Drugs Sales by Region 3.5.2 Asia Pacific Multiple Sclerosis Drugs Sales by Region 3.5.3 China 3.5.4 Japan 3.5.5 South Korea 3.5.6 India 3.5.7 Australia 3.5.8 Taiwan 3.5.9 Indonesia 3.5.10 Thailand 3.5.11 Malaysia 3.5.12 Philippines 3.5.13 Vietnam 3.6 Latin America Multiple Sclerosis Drugs Market Facts & Figures by Country 3.6.1 Latin America Multiple Sclerosis Drugs Sales by Country 3.6.2 Latin America Multiple Sclerosis Drugs Sales by Country 3.6.3 Mexico 3.6.4 Brazil 3.6.5 Argentina 3.7 Middle East and Africa Multiple Sclerosis Drugs Market Facts & Figures by Country 3.7.1 Middle East and Africa Multiple Sclerosis Drugs Sales by Country 3.7.2 Middle East and Africa Multiple Sclerosis Drugs Sales by Country 3.7.3 Turkey 3.7.4 Saudi Arabia 3.7.5 U.A.E 4 Global Multiple Sclerosis Drugs Historic Market Analysis by Type 4.1 Global Multiple Sclerosis Drugs Sales Market Share by Type (2015-2020) 4.2 Global Multiple Sclerosis Drugs Revenue Market Share by Type (2015-2020) 4.3 Global Multiple Sclerosis Drugs Price Market Share by Type (2015-2020) 4.4 Global Multiple Sclerosis Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Global Multiple Sclerosis Drugs Historic Market Analysis by Application 5.1 Global Multiple Sclerosis Drugs Sales Market Share by Application (2015-2020) 5.2 Global Multiple Sclerosis Drugs Revenue Market Share by Application (2015-2020) 5.3 Global Multiple Sclerosis Drugs Price by Application (2015-2020) 6 Company Profiles and Key Figures in Multiple Sclerosis Drugs Business 6.1 Biogen 6.1.1 Corporation Information 6.1.2 Biogen Description, Business Overview 6.1.3 Biogen Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2015-2020) 6.1.4 Biogen Products Offered 6.1.5 Biogen Recent Development 6.2 Sanofi 6.2.1 Sanofi Corporation Information 6.2.2 Sanofi Description, Business Overview 6.2.3 Sanofi Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2015-2020) 6.2.4 Sanofi Products Offered 6.2.5 Sanofi Recent Development 6.3 Novartis 6.3.1 Novartis Corporation Information 6.3.2 Novartis Description, Business Overview 6.3.3 Novartis Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2015-2020) 6.3.4 Novartis Products Offered 6.3.5 Novartis Recent Development 6.4 Teva 6.4.1 Teva Corporation Information 6.4.2 Teva Description, Business Overview 6.4.3 Teva Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2015-2020) 6.4.4 Teva Products Offered 6.4.5 Teva Recent Development 6.5 Merck KGaA 6.5.1 Merck KGaA Corporation Information 6.5.2 Merck KGaA Description, Business Overview 6.5.3 Merck KGaA Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2015-2020) 6.5.4 Merck KGaA Products Offered 6.5.5 Merck KGaA Recent Development 6.6 Bayer 6.6.1 Bayer Corporation Information 6.6.2 Bayer Description, Business Overview 6.6.3 Bayer Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2015-2020) 6.6.4 Bayer Products Offered 6.6.5 Bayer Recent Development 6.7 ACORDA 6.6.1 ACORDA Corporation Information 6.6.2 ACORDA Description, Business Overview 6.6.3 ACORDA Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2015-2020) 6.4.4 ACORDA Products Offered 6.7.5 ACORDA Recent Development 6.8 Mallinckrodt 6.8.1 Mallinckrodt Corporation Information 6.8.2 Mallinckrodt Description, Business Overview 6.8.3 Mallinckrodt Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2015-2020) 6.8.4 Mallinckrodt Products Offered 6.8.5 Mallinckrodt Recent Development 7 Multiple Sclerosis Drugs Manufacturing Cost Analysis 7.1 Multiple Sclerosis Drugs Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Key Raw Materials Price Trend 7.1.3 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of Multiple Sclerosis Drugs 7.4 Multiple Sclerosis Drugs Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 Multiple Sclerosis Drugs Distributors List 8.3 Multiple Sclerosis Drugs Customers 9 Market Dynamics 9.1 Market Trends 9.2 Opportunities and Drivers 9.3 Challenges 9.4 Porter's Five Forces Analysis 10 Global Market Forecast 10.1 Global Multiple Sclerosis Drugs Market Estimates and Projections by Type 10.1.1 Global Forecasted Sales of Multiple Sclerosis Drugs by Type (2021-2026) 10.1.2 Global Forecasted Revenue of Multiple Sclerosis Drugs by Type (2021-2026) 10.2 Multiple Sclerosis Drugs Market Estimates and Projections by Application 10.2.1 Global Forecasted Sales of Multiple Sclerosis Drugs by Application (2021-2026) 10.2.2 Global Forecasted Revenue of Multiple Sclerosis Drugs by Application (2021-2026) 10.3 Multiple Sclerosis Drugs Market Estimates and Projections by Region 10.3.1 Global Forecasted Sales of Multiple Sclerosis Drugs by Region (2021-2026) 10.3.2 Global Forecasted Revenue of Multiple Sclerosis Drugs by Region (2021-2026) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

List of Tables Table 1. Global Multiple Sclerosis Drugs Sales (K Units) Growth Rate Comparison by Type (2015-2026) Table 2. Global Multiple Sclerosis Drugs Sales (K Units) Comparison by Application: 2020 VS 2026 Table 3. Global Multiple Sclerosis Drugs Market Size by Type (K Units) (US$ Million) (2020 VS 2026) Table 4. Global Key Multiple Sclerosis Drugs Manufacturers Covered in This Study Table 5. Global Multiple Sclerosis Drugs Sales (K Units) by Manufacturers (2015-2020) Table 6. Global Multiple Sclerosis Drugs Sales Share by Manufacturers (2015-2020) Table 7. Global Multiple Sclerosis Drugs Revenue (Million USD) by Manufacturers (2015-2020) Table 8. Global Multiple Sclerosis Drugs Revenue Share by Manufacturers (2015-2020) Table 9. Global Market Multiple Sclerosis Drugs Average Price (USD/Unit) of Key Manufacturers (2015-2020) Table 10. Manufacturers Multiple Sclerosis Drugs Sales Sites and Area Served Table 11. Manufacturers Multiple Sclerosis Drugs Product Types Table 12. Global Multiple Sclerosis Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global Multiple Sclerosis Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Multiple Sclerosis Drugs as of 2019) Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Main Points Interviewed from Key Multiple Sclerosis Drugs Players Table 16. Global Multiple Sclerosis Drugs Sales (K Units) by Region (2015-2020) Table 17. Global Multiple Sclerosis Drugs Sales Market Share by Region (2015-2020) Table 18. Global Multiple Sclerosis Drugs Revenue (Million US$) by Region (2015-2020) Table 19. Global Multiple Sclerosis Drugs Revenue Market Share by Region (2015-2020) Table 20. North America Multiple Sclerosis Drugs Sales by Country (2015-2020) (K Units) Table 21. North America Multiple Sclerosis Drugs Sales Market Share by Country (2015-2020) Table 22. North America Multiple Sclerosis Drugs Revenue by Country (2015-2020) (US$ Million) Table 23. North America Multiple Sclerosis Drugs Revenue Market Share by Country (2015-2020) Table 24. Europe Multiple Sclerosis Drugs Sales by Country (2015-2020) (K Units) Table 25. Europe Multiple Sclerosis Drugs Sales Market Share by Country (2015-2020) Table 26. Europe Multiple Sclerosis Drugs Revenue by Country (2015-2020) (US$ Million) Table 27. Europe Multiple Sclerosis Drugs Revenue Market Share by Country (2015-2020) Table 28. Asia Pacific Multiple Sclerosis Drugs Sales by Region (2015-2020) (K Units) Table 29. Asia Pacific Multiple Sclerosis Drugs Sales Market Share by Region (2015-2020) Table 30. Asia Pacific Multiple Sclerosis Drugs Revenue by Region (2015-2020) (US$ Million) Table 31. Asia Pacific Multiple Sclerosis Drugs Revenue Market Share by Region (2015-2020) Table 32. Latin America Multiple Sclerosis Drugs Sales by Country (2015-2020) (K Units) Table 33. Latin America Multiple Sclerosis Drugs Sales Market Share by Country (2015-2020) Table 34. Latin America Multiple Sclerosis Drugs Revenue by Country (2015-2020) (US$ Million) Table 35. Latin America Multiple Sclerosis Drugs Revenue Market Share by Country (2015-2020) Table 36. Middle East and Africa Multiple Sclerosis Drugs Sales by Country (2015-2020) (K Units) Table 37. Middle East and Africa Multiple Sclerosis Drugs Sales Market Share by Country (2015-2020) Table 38. Middle East and Africa Multiple Sclerosis Drugs Revenue by Country (2015-2020) (US$ Million) Table 39. Middle East and Africa Multiple Sclerosis Drugs Revenue Market Share by Country (2015-2020) Table 40. Global Multiple Sclerosis Drugs Sales (K Units) by Type (2015-2020) Table 41. Global Multiple Sclerosis Drugs Sales Share by Type (2015-2020) Table 42. Global Multiple Sclerosis Drugs Revenue (Million US$) by Type (2015-2020) Table 43. Global Multiple Sclerosis Drugs Revenue Share by Type (2015-2020) Table 44. Global Multiple Sclerosis Drugs Price (USD/Unit) by Type (2015-2020) Table 45. Global Multiple Sclerosis Drugs Sales (K Units) by Application (2015-2020) Table 46. Global Multiple Sclerosis Drugs Sales Market Share by Application (2015-2020) Table 47. Global Multiple Sclerosis Drugs Sales Growth Rate by Application (2015-2020) Table 48. Biogen Corporation Information Table 49. Biogen Description and Business Overview Table 50. Biogen Multiple Sclerosis Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 51. Biogen Main Product Table 52. Biogen Recent Development Table 53. Sanofi Corporation Information Table 54. Sanofi Description and Business Overview Table 55. Sanofi Multiple Sclerosis Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 56. Sanofi Main Product Table 57. Sanofi Recent Development Table 58. Novartis Corporation Information Table 59. Novartis Description and Business Overview Table 60. Novartis Multiple Sclerosis Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 61. Novartis Main Product Table 62. Novartis Recent Development Table 63. Teva Corporation Information Table 64. Teva Description and Business Overview Table 65. Teva Multiple Sclerosis Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 66. Teva Main Product Table 67. Teva Recent Development Table 68. Merck KGaA Corporation Information Table 69. Merck KGaA Description and Business Overview Table 70. Merck KGaA Multiple Sclerosis Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 71. Merck KGaA Main Product Table 72. Merck KGaA Recent Development Table 73. Bayer Corporation Information Table 74. Bayer Description and Business Overview Table 75. Bayer Multiple Sclerosis Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 76. Bayer Main Product Table 77. Bayer Recent Development Table 78. ACORDA Corporation Information Table 79. ACORDA Description and Business Overview Table 80. ACORDA Multiple Sclerosis Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 81. ACORDA Main Product Table 82. ACORDA Recent Development Table 83. Mallinckrodt Corporation Information Table 84. Mallinckrodt Description and Business Overview Table 85. Mallinckrodt Multiple Sclerosis Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 86. Mallinckrodt Main Product Table 87. Mallinckrodt Recent Development Table 88. Production Base and Market Concentration Rate of Raw Material Table 89. Key Suppliers of Raw Materials Table 90. Multiple Sclerosis Drugs Distributors List Table 91. Multiple Sclerosis Drugs Customers List Table 92. Multiple Sclerosis Drugs Market Trends Table 93. Multiple Sclerosis Drugs Opportunities and Drivers Table 94. Multiple Sclerosis Drugs Market Challenges Table 95. Global Multiple Sclerosis Drugs Sales (K Units) Forecast by Type (2021-2026) Table 96. Global Multiple Sclerosis Drugs Sales Market Share Forecast by Type (2021-2026) Table 97. Global Multiple Sclerosis Drugs Revenue (Million US$) Forecast by Type (2021-2026) Table 98. Global Multiple Sclerosis Drugs Revenue (Million US$) Market Share Forecast by Type (2021-2026) Table 99. Global Multiple Sclerosis Drugs Sales (K Units) Forecast by Application (2021-2026) Table 100. Global Multiple Sclerosis Drugs Revenue (Million US$) Forecast by Application (2021-2026) Table 101. Global Multiple Sclerosis Drugs Sales (K Units) Forecast by Region (2021-2026) Table 102. Global Multiple Sclerosis Drugs Sales Market Share Forecast by Region (2021-2026) Table 103. Global Multiple Sclerosis Drugs Revenue Forecast by Region (2021-2026) (US$ Million) Table 104. Global Multiple Sclerosis Drugs Revenue Market Share Forecast by Region (2021-2026) Table 105. Research Programs/Design for This Report Table 106. Key Data Information from Secondary Sources Table 107. Key Data Information from Primary Sources List of Figures Figure 1. Picture of Multiple Sclerosis Drugs Figure 2. Global Multiple Sclerosis Drugs Sales Market Share by Type: 2020 VS 2026 Figure 3. Injectable Medications Product Picture Figure 4. Oral Medications Product Picture Figure 5. Others Product Picture Figure 6. Global Multiple Sclerosis Drugs Consumption Market Share by Application: 2020 VS 2026 Figure 7. Adults Figure 8. Children Figure 9. Global Multiple Sclerosis Drugs Market Size 2015-2026 (US$ Million) Figure 10. Global Multiple Sclerosis Drugs Sales Capacity (K Units) (2015-2026) Figure 11. Global Multiple Sclerosis Drugs Market Size Market Share by Region: 2020 Versus 2026 Figure 12. Multiple Sclerosis Drugs Sales Share by Manufacturers in 2020 Figure 13. Global Multiple Sclerosis Drugs Revenue Share by Manufacturers in 2019 Figure 14. The Global 5 and 10 Largest Players: Market Share by Multiple Sclerosis Drugs Revenue in 2019 Figure 15. Multiple Sclerosis Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019 Figure 16. Global Multiple Sclerosis Drugs Sales Market Share by Region (2015-2020) Figure 17. Global Multiple Sclerosis Drugs Sales Market Share by Region in 2019 Figure 18. Global Multiple Sclerosis Drugs Revenue Market Share by Region (2015-2020) Figure 19. Global Multiple Sclerosis Drugs Revenue Market Share by Region in 2019 Figure 20. North America Multiple Sclerosis Drugs Sales Market Share by Country in 2019 Figure 21. North America Multiple Sclerosis Drugs Revenue Market Share by Country in 2019 Figure 22. U.S. Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units) Figure 23. U.S. Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 24. Canada Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units) Figure 25. Canada Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 26. Europe Multiple Sclerosis Drugs Sales Market Share by Country in 2019 Figure 27. Europe Multiple Sclerosis Drugs Revenue Market Share by Country in 2019 Figure 28. Germany Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units) Figure 29. Germany Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 30. France Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units) Figure 31. France Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 32. U.K. Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units) Figure 33. U.K. Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 34. Italy Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units) Figure 35. Italy Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 36. Russia Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units) Figure 37. Russia Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 38. Asia Pacific Multiple Sclerosis Drugs Sales Market Share by Region in 2019 Figure 39. Asia Pacific Multiple Sclerosis Drugs Revenue Market Share by Region in 2019 Figure 40. China Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units) Figure 41. China Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 42. Japan Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units) Figure 43. Japan Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 44. South Korea Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units) Figure 45. South Korea Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 46. India Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units) Figure 47. India Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 48. Australia Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units) Figure 49. Australia Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 50. Taiwan Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units) Figure 51. Taiwan Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 52. Indonesia Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units) Figure 53. Indonesia Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 54. Thailand Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units) Figure 55. Thailand Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 56. Malaysia Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units) Figure 57. Malaysia Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 58. Philippines Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units) Figure 59. Philippines Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 60. Vietnam Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units) Figure 61. Vietnam Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 62. Latin America Multiple Sclerosis Drugs Sales Market Share by Country in 2019 Figure 63. Latin America Multiple Sclerosis Drugs Revenue Market Share by Country in 2019 Figure 64. Mexico Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units) Figure 65. Mexico Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 66. Brazil Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units) Figure 67. Brazil Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 68. Argentina Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units) Figure 69. Argentina Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 70. Middle East and Africa Multiple Sclerosis Drugs Sales Market Share by Country in 2019 Figure 71. Middle East and Africa Multiple Sclerosis Drugs Revenue Market Share by Country in 2019 Figure 72. Turkey Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units) Figure 73. Turkey Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 74. Saudi Arabia Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units) Figure 75. Saudi Arabia Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 76. U.A.E Multiple Sclerosis Drugs Sales Growth Rate (2015-2020) (K Units) Figure 77. U.A.E Multiple Sclerosis Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 78. Sales Market Share of Multiple Sclerosis Drugs by Type (2015-2020) Figure 79. Sales Market Share of Multiple Sclerosis Drugs by Type in 2020 Figure 80. Global Multiple Sclerosis Drugs Market Share by Price Range (2015-2020) Figure 81. Revenue Market Share of Multiple Sclerosis Drugs by Type in 2019 Figure 82. Global Multiple Sclerosis Drugs Sales Growth by Type (2015-2020) (K Units) Figure 83. Sales Market Share of Multiple Sclerosis Drugs by Application (2015-2020) Figure 84. Sales Market Share of Multiple Sclerosis Drugs by Application in 2020 Figure 85. Revenue Share of Multiple Sclerosis Drugs by Application (2015-2020) Figure 86. Revenue Share of Multiple Sclerosis Drugs by Application in 2020 Figure 87. Key Raw Materials Price Trend Figure 88. Manufacturing Cost Structure of Multiple Sclerosis Drugs Figure 89. Manufacturing Process Analysis of Multiple Sclerosis Drugs Figure 90. Multiple Sclerosis Drugs Industrial Chain Analysis Figure 91. Channels of Distribution Figure 92. Distributors Profiles Figure 93. Porter's Five Forces Analysis Figure 94. Bottom-up and Top-down Approaches for This Report Figure 95. Data Triangulation Figure 96. Key Executives Interviewed

Biogen Sanofi Novartis Teva Merck KGaA Bayer ACORDA Mallinckrodt